Nancy S. Lurker's appointment to Alkermes' Board is viewed positively, bringing deep industry experience and commercial expertise. Her broad skills are expected to drive growth of existing products, portfolio expansion, and new product launches.
Alkermes' surplus of cash over debt and its ability to convert EBIT to free cash flow indicate a conservative balance sheet and low risk in its debt management.
Although Alkermes' share price has recently dipped, its long-term business trends are positive. Insider purchases, often seen as a good omen by investors, add further optimism.
阿爾凱默斯股票討論區
2023Q1營收增長3.3%,營業利潤和淨利潤虧損均大幅擴大,目前看不到投資價值。
Just got FDA approved and have another drug phase1/2 on 4 June!!
暫無評論